Zacks small cap research.

By Brad Sorensen, CFA NASDAQ:ONVO READ THE FULL ONVO RESEARCH REPORT Organovo (NASDAQ:ONVO) reported its fiscal 2Q earnings and results were roughly inline with our expectations and illustrate to us that the company continues to progress toward bringing important products to market. Specifically, the company reported: • Earnings of -$0.46 per share, in line with estimates as expenses remained2 days ago · This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of ... Zacks Small Cap Research. BBLG: BBLG Has Solid Cash and Is Advancing Testing. Read full article. Zacks Small Cap Research. May 16, 2023 at 7:20 AM ...Aug 1, 2023 · read the full nexcf research report Nextech (OTC:NEXCF) preannounced Q2 revenues of $1.4 million, up $100,000 sequentially from Q1 and 153% from Q2 2022. It expects gross margins to be the same as in Q1 at 38%. Ann H. Heffron, CFA, CPA is a Senior Analyst at Zacks Investment Research. Ann has over 25 years of investment research experience, primarily working as a securities analyst following banks and other financial institutions for a number of firms in the Chicago area. ... Prior to joining Zacks, Ann was a Senior Vice President at Zurich Scudder ...

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Zacks Rank N/A Correlation Study Complete Zacks Small-Cap Research John D. Vandermosten, CFA Sponsored – Impartial – Comprehensive scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 September 23, 2022 312-265-9588 / [email protected] Revenue (In millions of USD) Q1 Q2 Q3 Q4 Year

John Vandermosten, CFA is currently a Senior Analyst for Zacks Investment Research where he covers a portfolio of small cap biotechnology names. His background includes 19 years of experience in a variety of investment management and research roles across all market cap ranges and throughout the capital structure. John is a frequent moderator ...

May 15, 2023 · Yes, absolutely. Zacks is worth it. Given that the stocks they rate as a #1 Strong Buy have beat the SP500 by 13.9% on average for the last 34 years, their system works. And the fact that the stocks they rate as a #5 Strong Sell have underperformed the market by 8.4% all but proves their system. Zacks Equity Research November 23, 2023. CVX Quick Quote CVX ... Overall, they are usually a stable option, with less risk and more sure-fire cash flows than …SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …By Thomas Kerr, CFA. NASDAQ:GRIL. READ THE FULL GRIL RESEARCH REPORT. Muscle Maker Inc. (NASDAQ:GRIL), has evolved into a diversified, global food company with two distinct business units: 1) Sadot LLC – an international agricultural commodity supply-chain organization and 2) MMI Restaurant Group – an operator and franchisor of 50+ healthier-for-you fast casual concepts plus a subscription ...We estimate the company has sufficient capital to fund operations into the third quarter of 2023. On November 22, 2022, Qualigen announced a 1-for-10 reverse stock split, thus we estimate that the company currently has approximately 4.2 million shares outstanding and, when factoring in stock options and warrants, a fully diluted share count …

Nov 10, 2023 · LGVN Continues to Show Progress. Longeveron (NASDAQ:LGVN) released its 3Q earnings results: • Revenues of $200,000, which was slightly lower than last year due to completion of some grant-funded trials. • Earnings per share of -$0.28, which is in the range of what we were expecting. During 3Q 2023, Longeveron completed a direct offering of ...

Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE. 1. Reviva RECOVER Topline Results Data Presentation, October 30, 2023.

By John Vandermosten, CFA. NASDAQ:RVPH. READ THE FULL RVPH RESEARCH REPORT. 2Q:23 Financial and Operational Results. On August 15, 2023, Reviva Pharmaceutical Holdings, Inc. (NASDAQ:RVPH) reported 2Q:23 financial and operational results and filed its Form 10-Q with the SEC. Since our previous update in …By David Bautz, PhD NASDAQ:ABEO READ THE FULL ABEO RESEARCH REPORT We are initiating coverage of Abeona Therapeutics Inc. (NASDAQ:ABEO) with a valuation of $10.00. Abeona is a biopharmaceutical company developing cell and gene therapies for rare genetic diseases. Its lead clinical program, EB-101, is an autologous cell therapy in development for the treatment of recessive dystrophic epidermolysisManagement reiterated its outlook of revenues between $14.0 and $15.0 million in 2023. Operational and scientific highlights for 2Q:23 and to date include: Import license granted for Indonesia, Malaysia and South Africa – April 2023. Teijin license fee remitted – April 2023. Three patent issue notifications received – April 2023.A division of Zacks Investment Research, Zacks Small-Cap Research covers small and micro-cap companies under-followed by Wall Street. Our in-depth fundamental research reports, commentary ...DIREXION DAILY SMALL CAP BULL 3X SHARES. The Direxion Daily Small Cap Bull 3x Shares seeks daily investment results, before fees and expenses, of 300% of the performance of the Russell 2000 Index ...

About Zacks Small-Cap Research Zacks/SCR prepares company-sponsored, independent research and related content for distribution through a multitude of investor and media channels, both traditional ...In mid-July, Lantern announced the start of the Harmonic trial that will evaluate LP-300 in never smokers with non-small cell lung cancer (NSCLC). 90 subjects are expected to enroll in the Phase II study at 15 – 20 sites around the United States with enrollment expected to last from 12 to 16 months. It will target never smokers with lung ...Nov 14, 2023 · 11/14/2023 By Brad Sorensen, CFA NASDAQ:MIRA READ THE FULL MIRA RESEARCH REPORT MIRA (NASDAQ:MIRA) reported 3Q earnings of -$0.26 per share as it continues to test and research its potential... Zacks Rank N/A FY21 Results; IO Revenues Analysis Zacks Small-Cap Research John D. Vandermosten, CFA Sponsored – Impartial – Comprehensive scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 January 11, 2022 312-265-9588 / [email protected] Revenue Q1 Q2 Q3 Q4 Year (Dec) (Mar) (Jun) (Sep) (Sep)Zacks Investment Research is a Chicago-based research and money management firm founded in 1978 to provide institutional investors with quantitative models ...Sep 29, 2023 · By John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT While the clinical trial for LP-300 is ongoing in never-smoker, non-small cell lung cancer patients, Lantern Pharma, Inc. (NASDAQ:LTRN) has been busy advancing some of its earlier stage assets including LP-184 and LP-284. These small molecule acylfulvenes are chemically related as LP-284 is the positive enantiomer of LP-184. When it comes to wheels, one small but important component that often goes unnoticed is the wheel center cap. These caps not only add a touch of style to your vehicle’s wheels but also serve several practical functions.

06/12/2023. UHAL: U-Haul Holding Company Reports Financial Results for Fiscal 2023; Demand for truck rentals slowed in the second half of FY2023. Management aspires to hold the market share gains and has expectations that the self-moving market will stabilize in FY2024. 06/08/2023.By Brad Sorensen, CFA OTC:FRXIF READ THE FULL FRXIF RESEARCH REPORT Demand continues to increase for a flame retardant that doesn’t have toxic chemicals and the Nofia product from FRX Innovations (OTC:FRXIF), an eco-friendly flame retardant solution, is the perfect solution. Studies previously cited by the FRX note that over 60% of fire-retardant plastic formulations are based on

By John Vandermosten, CFA NASDAQ:RVPH RP5063: Retroactive Comparison Against 32 Antipsychotics An estimated 0.25% to 1% of the global population suffers from schizophrenia. To address this estimated 20 million individuals with the chronic disorder there are numerous antipsychotics approved for use. However, a high discontinuation rate due to suboptimal efficacy and serious side effects reveals anA conference call with investors and analysts was held immediately following the release. 2Q:23 revenues of $3.6 million were ahead of our initial estimates and matched revised company guidance. Net loss per share was ($1.03). Management reiterated its outlook of revenues between $14.0 and $15.0 million in 2023.SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Nov 18, 2022 · OTC:NEXCF. READ THE FULL NEXCF RESEARCH REPORT. Nextech AR’s (OTC:NEXCF) Q3 report showed a rapid uptake of its AR 3D model subscription business which grew 192% sequentially. It plans to deliver $700,000 worth of models to Amazon (we believe) alone in Q4 and the business continues to thrive. Just as importantly, the company has reduced its ... Mar 23, 2023 · By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT 2022 Operational and Financial Results On March 22, 2023, BioLineRx Ltd. (NASDAQ:BLRX) reported 2022 operational and financial results in a press release concurrent with the filing of Form 20-F. A conference call and webcast were hosted later that morning. Key highlights since the previous earnings update in November include By Brad Sorensen, CFA NASDAQ:ONVO READ THE FULL ONVO RESEARCH REPORT Organovo (NASDAQ:ONVO) reported its fiscal 2Q earnings and results were roughly inline with our expectations and illustrate to us that the company continues to progress toward bringing important products to market. Specifically, the company reported: • Earnings of -$0.46 per share, in line with estimates as expenses remained1. Strong Balance Sheet – MediciNova exited the first quarter of 2023 with approximately $55.3 million in cash and cash equivalents. Due to a low operating cash burn rate, we estimate this is enough to fund operations for at least the next four years. The financial markets continue to be difficult for small-cap biotech companies, and those ...SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …

Zacks Small-Cap Research Lisa R. Thompson 312-265-9154 [email protected] scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 January 18, 2022 Preannounces Q4 Revenues of $8.8 Million up 275% Based on a blended enterprise value to sales multiple of its peers of 5.85 times, we believe

Financial Results. In its latest fiscal quarter ending December 31 st, IBS generated total revenues of $626,000 compared to $178,000 in the prior year period. 2Q:23 revenues included a component from both Intelligent Fingerprinting (IFP) and government support revenue while 2Q:22 revenues only included the government support component ...

Dec 1, 2022 · By David Bautz, PhD. NASDAQ:QLGN. READ THE FULL QLGN RESEARCH REPORT. Business Update . Preclinical Data on QN-302 Presented at AACR Conference on Pancreatic Cancer . In September 2022, Qualigen Therapeutics, Inc. (NASDAQ:QLGN) announced the presentation of two posters on QN-302 at the AACR 8 th Special Conference on Pancreatic Cancer. A division of Zacks Investment Research, Zacks Small-Cap Research covers small and micro-cap companies under-followed by Wall Street. Our in-depth fundamental research reports, commentary ...Zacks Rank N/A INBS: Australia Off to a Strong Start Zacks Small-Cap Research John D. Vandermosten, CFA Sponsored – Impartial – Comprehensive scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 September 5, 2023 312-265-9588 / [email protected] ESTIMATES Revenue ns of USD) Q1 Q2 Q3 Q4 Year When it comes to maintaining the aesthetics and functionality of your wheels, OEM wheel center caps play a crucial role. These small but significant accessories not only add a touch of style to your vehicle’s appearance but also provide ess...Investrade has good news to share - we are providing all customers FREE Snapshot research reports from Zacks Investment Research. There are reports on 4400 ...06/12/2023. UHAL: U-Haul Holding Company Reports Financial Results for Fiscal 2023; Demand for truck rentals slowed in the second half of FY2023. Management aspires to hold the market share gains and has expectations that the self-moving market will stabilize in FY2024. 06/08/2023.Zacks Investment Research has three different main subscription plans: Zacks Premium, Zacks Investor Collection, and Zacks Ultimate. Zacks Premium costs …Q4 2022 gross margin increased to 30.9% from 24.3% a year ago and 29.2% in Q3 2022. The increase was primarily from the elimination of $20 million of low-margin revenues from the closure of the Japanese fab which were replaced by higher-margin sales generated from outside customers. Gross margin dollars increased by $25 million, or 25%.Zacks Small Cap Research. TENX: Prioritizing Levosimendan. Read full article. Zacks Small Cap Research. May 22, 2023 at 6:44 AM ...The estimate for 2022 is up $1.56 (44.8%) in the last 90 days. The 2023 estimate is up $1.34 (33.6%) during the same time period. The earnings beat in the last quarter of 91.5% is greater than the ...By John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT While the clinical trial for LP-300 is ongoing in never-smoker, non-small cell lung cancer patients, Lantern Pharma, Inc. (NASDAQ:LTRN) has been busy advancing some of its earlier stage assets including LP-184 and LP-284. These small molecule acylfulvenes are chemically related as LP-284 is the positive enantiomer of LP-184.

When it comes to wheels, one small but important component that often goes unnoticed is the wheel center cap. These caps not only add a touch of style to your vehicle’s wheels but also serve several practical functions.Apr 17, 2023 · Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE. 1. Screenshot of interview with Allarity CEO, Jim Cullem. 2. Oct 31, 2023 · Fund Description. The fund was incepted in May 2000 and is managed by Franklin Advisers. The objective of this fund is long-term capital growth. The fund invests at least 80% of its net assets in ... Zacks Rank N/A BIOR: Precision Release – Surgical Strike on the GI Tract Zacks Small-Cap Research Joh Sponsored – Impartial – Comprehensive scr.zacks.com 10 S. …Instagram:https://instagram. allstate umbrella policy costcarg'today moversalternative investment brokers Zacks Small-Cap Research Lisa R. Thompson 312-265-9154 [email protected] scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 January 18, 2022 Preannounces Q4 Revenues of $8.8 Million up 275% Based on a blended enterprise value to sales multiple of its peers of 5.85 times, we believeA division of Zacks Investment Research, Zacks Small-Cap Research covers small and micro-cap companies under-followed by Wall Street. Our in-depth fundamental research reports, commentary ... ansheur buschfutures trading advice Image: Bigstock 5 Top-Ranked Small-Cap Stocks to Boost Your Portfolio in 2021 (revised) Nalak Das December 14, 2020 TITN HZO STRT Better trading starts … forex cryptocurrency Novonix Cathode Materials is also expected to play a key role in the growing demand for batteries. Last month NVX launched a new pilot production facility for cathode materials in a new 35,000-square-foot facility. The facility enables Novonix to demonstrate the feasibility of large-scale production.On February 6, 2023, Arrowhead announced financial results for the first quarter of fiscal year 2023 that ended December 31, 2022. The company reported revenue of approximately $62.5 million for the first quarter of fiscal year 2023 compared to approximately $27.4 million for the first quarter of fiscal year 2022.